STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...

Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...

Chitra Kannabiran, PhD, Kallam Anji Reddy Molecular Genetics Laboratory, Hyderabad Eye Research Foundation, Champalimaud Translational Centre, LV Prasad Eye Institute, Hyderabad 500 034, India ...

The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted rare pediatric disease designation to VG901 for retinitis pigmentosa. An independent data safety ...

Gene therapy may be the best hope for curing retinitis pigmentosa (RP), an inherited condition that usually leads to severe vision loss and blinds 1.5 million people worldwide. But there's a huge ...

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...

Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, ...